Poxel (FRA:7PO) Notes Receivable: €0.00 Mil (As of Jun. 2025)


FRA:7PO Poxel SA FRA:7PO
37 GF Score
Price €0.20
GF Value €1.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Notes Receivable?

Poxel FRA:7PO +1.81% 37 Notes Receivable is €0.00 Mil as of Jun. 2025. GuruFocus rates FRA:7PO with a GF Score™ of 37/100 and a GF Value™ of €1.30 (Possible Value Trap). The stock has 6 warning signs investors should review.

Poxel's Notes Receivable for the quarter that ended in Jun. 2025 was €0.00 Mil.

Poxel Notes Receivable Historical Data

* Premium members only.

The historical data trend for Poxel's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poxel Notes Receivable Chart

Poxel Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poxel Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7PO
37GF Score
Poxel SA FRA:7PO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Poxel Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Poxel (FRA:7PO) has a Notes Receivable of €0.00 Mil as of Jun. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Poxel and its competitors.
Is Poxel's Notes Receivable too high?
Poxel's current Notes Receivable is €0.00 Mil. Overall, Poxel has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Poxel's Notes Receivable compare to VRTX and REGN?
Poxel's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Poxel and its competitors. Poxel's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poxel stock overvalued right now?
Based on GuruFocus' analysis, Poxel (FRA:7PO) is currently considered Possible Value Trap. The stock's GF Value™ is €1.30, compared to a current price of €0.20 — trading 84.5% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Poxel's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Poxel (FRA:7PO), the current Notes Receivable is €0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Poxel (FRA:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.20 is trading 84.5% below its estimated GF Value™ of €1.30. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for FRA:7PO:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €1.30 vs. price of €0.20 (84.5% below fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poxel Business Description

Other Exchanges 0RA2:UKPOXEL:France
Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score

Get the complete analysis for FRA:7PO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€1.30
GF Value